ID   ACE2_HUMAN              Reviewed;         805 AA.
AC   Q9BYF1; C7ECU1; Q6UWP0; Q86WT0; Q9NRA7; Q9UFZ6;
DT   02-AUG-2005, integrated into UniProtKB/Swiss-Prot.
DT   02-AUG-2005, sequence version 2.
DT   10-MAY-2017, entry version 157.
DE   RecName: Full=Angiotensin-converting enzyme 2;
DE            EC=3.4.17.23;
DE   AltName: Full=ACE-related carboxypeptidase;
DE   AltName: Full=Angiotensin-converting enzyme homolog;
DE            Short=ACEH;
DE   AltName: Full=Metalloprotease MPROT15;
DE   Contains:
DE     RecName: Full=Processed angiotensin-converting enzyme 2;
DE   Flags: Precursor;
GN   Name=ACE2; ORFNames=UNQ868/PRO1885;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, FUNCTION,
RP   AND ENZYME REGULATION.
RC   TISSUE=Heart;
RX   PubMed=10969042; DOI=10.1161/01.RES.87.5.e1;
RA   Donoghue M., Hsieh F., Baronas E., Godbout K., Gosselin M.,
RA   Stagliano N., Donovan M., Woolf B., Robison K., Jeyaseelan R.,
RA   Breitbart R.E., Acton S.;
RT   "A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2)
RT   converts angiotensin I to angiotensin 1-9.";
RL   Circ. Res. 87:E1-E9(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY,
RP   GLYCOSYLATION, FUNCTION, AND ENZYME REGULATION.
RC   TISSUE=Lymphoma;
RX   PubMed=10924499; DOI=10.1074/jbc.M002615200;
RA   Tipnis S.R., Hooper N.M., Hyde R., Karran E., Christie G.,
RA   Turner A.J.;
RT   "A human homolog of angiotensin-converting enzyme. Cloning and
RT   functional expression as a captopril-insensitive carboxypeptidase.";
RL   J. Biol. Chem. 275:33238-33243(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY,
RP   SUBCELLULAR LOCATION, AND ENZYME REGULATION.
RC   TISSUE=Testis;
RX   PubMed=15231706; DOI=10.1210/en.2004-0443;
RA   Douglas G.C., O'Bryan M.K., Hedger M.P., Lee D.K.L., Yarski M.A.,
RA   Smith A.I., Lew R.A.;
RT   "The novel angiotensin-converting enzyme (ACE) homolog, ACE2, is
RT   selectively expressed by adult Leydig cells of the testis.";
RL   Endocrinology 145:4703-4711(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT SER-638.
RC   TISSUE=Lung, and Testis;
RX   PubMed=15937940; DOI=10.1002/ajmg.a.30779;
RA   Itoyama S., Keicho N., Hijikata M., Quy T., Phi N.C., Long H.T.,
RA   Ha L.D., Ban V.V., Matsushita I., Yanai H., Kirikae F., Kirikae T.,
RA   Kuratsuji T., Sasazuki T.;
RT   "Identification of an alternative 5'-untranslated exon and new
RT   polymorphisms of angiotensin-converting enzyme 2 gene: lack of
RT   association with SARS in the Vietnamese population.";
RL   Am. J. Med. Genet. A 136:52-57(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Suzuki Y., Watanabe M., Sugano S.;
RT   "Cloning, expression analysis and chromosomal localization of a novel
RT   ACE like enzyme.";
RL   Submitted (JUL-2000) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Southan C., Burgess N.;
RT   "MPROT15 polypeptide and MPROT15 polynucleotide.";
RL   Patent number CA2248987, 13-NOV-1999.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Li K.K.B., Yip C.W., Hon C.C., Lam C.Y., Leung F.C.C.;
RT   "Comparative susceptibility to SARS-CoV mediated by ACE2 protein of 15
RT   different species.";
RL   Submitted (JUN-2009) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S.,
RA   Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J.,
RA   Lewis L., Liao D., Mark M.R., Robbie E., Sanchez C., Schoenfeld J.,
RA   Seshagiri S., Simmons L., Singh J., Smith V., Stinson J., Vagts A.,
RA   Vandlen R.L., Watanabe C., Wieand D., Woods K., Xie M.-H.,
RA   Yansura D.G., Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A.D.,
RA   Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale
RT   effort to identify novel human secreted and transmembrane proteins: a
RT   bioinformatics assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ARG-26.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2-805 (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [13]
RP   PROTEIN SEQUENCE OF 679-689, IDENTIFICATION BY MASS SPECTROMETRY, AND
RP   INTERACTION WITH ITGB1.
RX   PubMed=15276642; DOI=10.1016/j.bbadis.2004.05.005;
RA   Lin Q., Keller R.S., Weaver B., Zisman L.S.;
RT   "Interaction of ACE2 and integrin beta1 in failing human heart.";
RL   Biochim. Biophys. Acta 1689:175-178(2004).
RN   [14]
RP   TISSUE SPECIFICITY.
RX   PubMed=12459472; DOI=10.1016/S0014-5793(02)03640-2;
RA   Harmer D., Gilbert M., Borman R., Clark K.L.;
RT   "Quantitative mRNA expression profiling of ACE 2, a novel homologue of
RT   angiotensin converting enzyme.";
RL   FEBS Lett. 532:107-110(2002).
RN   [15]
RP   BIOPHYSICOCHEMICAL PROPERTIES, ENZYME REGULATION, AND COFACTOR.
RX   PubMed=11815627; DOI=10.1074/jbc.M200581200;
RA   Vickers C., Hales P., Kaushik V., Dick L., Gavin J., Tang J.,
RA   Godbout K., Parsons T., Baronas E., Hsieh F., Acton S., Patane M.A.,
RA   Nichols A., Tummino P.;
RT   "Hydrolysis of biological peptides by human angiotensin-converting
RT   enzyme-related carboxypeptidase.";
RL   J. Biol. Chem. 277:14838-14843(2002).
RN   [16]
RP   FUNCTION (MICROBIAL INFECTION), INTERACTION WITH SARS-COV SPIKE
RP   GLYCOPROTEIN, GLYCOSYLATION, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=14647384; DOI=10.1038/nature02145;
RA   Li W., Moore M.J., Vasilieva N., Sui J., Wong S.-K., Berne M.A.,
RA   Somasundaran M., Sullivan J.L., Luzuriaga K., Greenough T.C., Choe H.,
RA   Farzan M.;
RT   "Angiotensin-converting enzyme 2 is a functional receptor for the SARS
RT   coronavirus.";
RL   Nature 426:450-454(2003).
RN   [17]
RP   INDUCTION.
RX   PubMed=15151696; DOI=10.1186/1741-7015-2-19;
RA   Goulter A.B., Goddard M.J., Allen J.C., Clark K.L.;
RT   "ACE2 gene expression is up-regulated in the human failing heart.";
RL   BMC Med. 2:19-19(2004).
RN   [18]
RP   TISSUE SPECIFICITY.
RX   PubMed=15141377; DOI=10.1002/path.1570;
RA   Hamming I., Timens W., Bulthuis M.L.C., Lely A.T., Navis G.J.,
RA   van Goor H.;
RT   "Tissue distribution of ACE2 protein, the functional receptor for SARS
RT   coronavirus. A first step in understanding SARS pathogenesis.";
RL   J. Pathol. 203:631-637(2004).
RN   [19]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH SARS-COV SPIKE
RP   GLYCOPROTEIN.
RX   PubMed=15452268; DOI=10.1128/JVI.78.20.11429-11433.2004;
RA   Li W., Greenough T.C., Moore M.J., Vasilieva N., Somasundaran M.,
RA   Sullivan J.L., Farzan M., Choe H.;
RT   "Efficient replication of severe acute respiratory syndrome
RT   coronavirus in mouse cells is limited by murine angiotensin-converting
RT   enzyme 2.";
RL   J. Virol. 78:11429-11433(2004).
RN   [20]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-90.
RC   TISSUE=Bile;
RX   PubMed=15084671; DOI=10.1074/mcp.M400015-MCP200;
RA   Kristiansen T.Z., Bunkenborg J., Gronborg M., Molina H.,
RA   Thuluvath P.J., Argani P., Goggins M.G., Maitra A., Pandey A.;
RT   "A proteomic analysis of human bile.";
RL   Mol. Cell. Proteomics 3:715-728(2004).
RN   [21]
RP   TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=15671045; DOI=10.1093/eurheartj/ehi114;
RA   Burrell L.M., Risvanis J., Kubota E., Dean R.G., MacDonald P.S.,
RA   Lu S., Tikellis C., Grant S.L., Lew R.A., Smith A.I., Cooper M.E.,
RA   Johnston C.I.;
RT   "Myocardial infarction increases ACE2 expression in rat and humans.";
RL   Eur. Heart J. 26:369-375(2005).
RN   [22]
RP   FUNCTION (MICROBIAL INFECTION), INTERACTION WITH SARS-COV SPIKE
RP   GLYCOPROTEIN, AND MUTAGENESIS.
RX   PubMed=15791205; DOI=10.1038/sj.emboj.7600640;
RA   Li W., Zhang C., Sui J., Kuhn J.H., Moore M.J., Luo S., Wong S.-K.,
RA   Huang I.-C., Xu K., Vasilieva N., Murakami A., He Y., Marasco W.A.,
RA   Guan Y., Choe H., Farzan M.;
RT   "Receptor and viral determinants of SARS-coronavirus adaptation to
RT   human ACE2.";
RL   EMBO J. 24:1634-1643(2005).
RN   [23]
RP   PROTEOLYTIC CLEAVAGE.
RX   PubMed=15983030; DOI=10.1074/jbc.M505111200;
RA   Lambert D.W., Yarski M., Warner F.J., Thornhill P., Parkin E.T.,
RA   Smith A.I., Hooper N.M., Turner A.J.;
RT   "Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated
RT   ectodomain shedding of the severe-acute respiratory syndrome-
RT   coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2
RT   (ACE2).";
RL   J. Biol. Chem. 280:30113-30119(2005).
RN   [24]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH HCOV-NL63 SPIKE
RP   GLYCOPROTEIN.
RX   PubMed=15897467; DOI=10.1073/pnas.0409465102;
RA   Hofmann H., Pyrc K., van der Hoek L., Geier M., Berkhout B.,
RA   Poehlmann S.;
RT   "Human coronavirus NL63 employs the severe acute respiratory syndrome
RT   coronavirus receptor for cellular entry.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:7988-7993(2005).
RN   [25]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-546.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [26]
RP   PROTEOLYTIC CLEAVAGE.
RX   PubMed=21563828; DOI=10.1021/bi200525y;
RA   Lai Z.W., Hanchapola I., Steer D.L., Smith A.I.;
RT   "Angiotensin-converting enzyme 2 ectodomain shedding cleavage-site
RT   identification: determinants and constraints.";
RL   Biochemistry 50:5182-5194(2011).
RN   [27]
RP   SUBCELLULAR LOCATION, PROTEOLYTIC CLEAVAGE, AND INTERACTION WITH
RP   TMPRSS2.
RX   PubMed=21068237; DOI=10.1128/JVI.02062-10;
RA   Shulla A., Heald-Sargent T., Subramanya G., Zhao J., Perlman S.,
RA   Gallagher T.;
RT   "A transmembrane serine protease is linked to the severe acute
RT   respiratory syndrome coronavirus receptor and activates virus entry.";
RL   J. Virol. 85:873-882(2011).
RN   [28]
RP   FUNCTION, SUBCELLULAR LOCATION, AND PROTEOLYTIC CLEAVAGE.
RX   PubMed=24227843; DOI=10.1128/JVI.02202-13;
RA   Heurich A., Hofmann-Winkler H., Gierer S., Liepold T., Jahn O.,
RA   Poehlmann S.;
RT   "TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by
RT   TMPRSS2 augments entry driven by the severe acute respiratory syndrome
RT   coronavirus spike protein.";
RL   J. Virol. 88:1293-1307(2014).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 19-615, X-RAY CRYSTALLOGRAPHY
RP   (3.0 ANGSTROMS) OF 19-615 IN COMPLEX WITH MLN-4760, DISULFIDE BONDS,
RP   AND GLYCOSYLATION AT ASN-53; ASN-90; ASN-103; ASN-322; ASN-432 AND
RP   ASN-546.
RX   PubMed=14754895; DOI=10.1074/jbc.M311191200;
RA   Towler P., Staker B., Prasad S.G., Menon S., Tang J., Parsons T.,
RA   Ryan D., Fisher M., Williams D., Dales N.A., Patane M.A.,
RA   Pantoliano M.W.;
RT   "ACE2 X-ray structures reveal a large hinge-bending motion important
RT   for inhibitor binding and catalysis.";
RL   J. Biol. Chem. 279:17996-18007(2004).
CC   -!- FUNCTION: Carboxypeptidase which converts angiotensin I to
CC       angiotensin 1-9, a peptide of unknown function, and angiotensin II
CC       to angiotensin 1-7, a vasodilator. Also able to hydrolyze apelin-
CC       13 and dynorphin-13 with high efficiency. May be an important
CC       regulator of heart function. {ECO:0000269|PubMed:10924499,
CC       ECO:0000269|PubMed:10969042, ECO:0000269|PubMed:14647384,
CC       ECO:0000269|PubMed:24227843}.
CC   -!- FUNCTION: (Microbial infection) Acts as a receptor for SARS
CC       coronavirus/SARS-CoV and human coronavirus NL63/HCoV-NL63.
CC       {ECO:0000269|PubMed:14647384, ECO:0000269|PubMed:15452268,
CC       ECO:0000269|PubMed:15791205, ECO:0000269|PubMed:15897467}.
CC   -!- CATALYTIC ACTIVITY: Angiotensin II + H(2)O = angiotensin-(1-7) +
CC       L-phenylalanine.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000269|PubMed:11815627};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000269|PubMed:11815627};
CC   -!- COFACTOR:
CC       Name=chloride; Xref=ChEBI:CHEBI:17996;
CC         Evidence={ECO:0000269|PubMed:11815627};
CC       Note=Binds 1 Cl(-) ion per subunit. {ECO:0000269|PubMed:11815627};
CC   -!- ENZYME REGULATION: Activated by chloride and fluoride, but not
CC       bromide. Inhibited by MLN-4760, cFP_Leu, and EDTA, but not by the
CC       ACE inhibitors linosipril, captopril and enalaprilat.
CC       {ECO:0000269|PubMed:10924499, ECO:0000269|PubMed:10969042,
CC       ECO:0000269|PubMed:11815627, ECO:0000269|PubMed:15231706}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=6.9 uM for angiotensin I {ECO:0000269|PubMed:11815627};
CC         KM=2 uM for angiotensin II {ECO:0000269|PubMed:11815627};
CC         KM=6.8 uM for apelin-13 {ECO:0000269|PubMed:11815627};
CC         KM=5.5 uM for dynorphin-13 {ECO:0000269|PubMed:11815627};
CC       pH dependence:
CC         Optimum pH is 6.5 in the presence of 1 M NaCl. Active from pH 6
CC         to 9. {ECO:0000269|PubMed:11815627};
CC   -!- SUBUNIT: Interacts with ITGB1. Interacts with the catalytically
CC       active form of TMPRSS2. {ECO:0000269|PubMed:14754895,
CC       ECO:0000269|PubMed:15276642, ECO:0000269|PubMed:21068237}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with SARS
CC       coronavirus/SARS-CoV and human coronavirus NL63/HCoV-NL63 spike
CC       glycoprotein (PubMed:14647384, PubMed:15452268, PubMed:15791205,
CC       PubMed:15897467). {ECO:0000269|PubMed:14647384,
CC       ECO:0000269|PubMed:15452268, ECO:0000269|PubMed:15791205,
CC       ECO:0000269|PubMed:15897467}.
CC   -!- SUBCELLULAR LOCATION: Processed angiotensin-converting enzyme 2:
CC       Secreted.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Cytoplasm {ECO:0000250}. Note=Detected in both cell
CC       membrane and cytoplasm in neurons. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9BYF1-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9BYF1-2; Sequence=VSP_014901, VSP_014902;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in endothelial cells from small and
CC       large arteries, and in arterial smooth muscle cells. Expressed in
CC       lung alveolar epithelial cells, enterocytes of the small
CC       intestine, Leydig cells and Sertoli cells (at protein level).
CC       Expressed in heart, kidney, testis, and gastrointestinal system.
CC       {ECO:0000269|PubMed:10924499, ECO:0000269|PubMed:10969042,
CC       ECO:0000269|PubMed:12459472, ECO:0000269|PubMed:15141377,
CC       ECO:0000269|PubMed:15231706, ECO:0000269|PubMed:15671045}.
CC   -!- INDUCTION: Up-regulated in failing heart.
CC       {ECO:0000269|PubMed:15151696, ECO:0000269|PubMed:15671045}.
CC   -!- PTM: N-glycosylation on Asn-90 may limit SARS infectivity.
CC       {ECO:0000269|PubMed:10924499, ECO:0000269|PubMed:14647384,
CC       ECO:0000269|PubMed:14754895, ECO:0000269|PubMed:15084671,
CC       ECO:0000269|PubMed:19159218}.
CC   -!- PTM: Proteolytic cleavage by ADAM17 generates a secreted form.
CC       Also cleaved by serine proteases: TMPRSS2, TMPRSS11D and
CC       HPN/TMPRSS1. {ECO:0000269|PubMed:15983030,
CC       ECO:0000269|PubMed:21068237, ECO:0000269|PubMed:21563828,
CC       ECO:0000269|PubMed:24227843}.
CC   -!- SIMILARITY: Belongs to the peptidase M2 family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/ace2/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF291820; AAF99721.1; -; mRNA.
DR   EMBL; AF241254; AAF78220.1; -; mRNA.
DR   EMBL; AY623811; AAT45083.1; -; mRNA.
DR   EMBL; AB193259; BAD99266.1; -; mRNA.
DR   EMBL; AB193260; BAD99267.1; -; mRNA.
DR   EMBL; AB046569; BAB40370.1; -; mRNA.
DR   EMBL; E39033; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; GQ262784; ACT66268.1; -; mRNA.
DR   EMBL; AY358714; AAQ89076.1; -; mRNA.
DR   EMBL; AY217547; AAO25651.1; -; Genomic_DNA.
DR   EMBL; CH471074; EAW98892.1; -; Genomic_DNA.
DR   EMBL; BC039902; AAH39902.1; -; mRNA.
DR   EMBL; BC048094; AAH48094.2; -; mRNA.
DR   EMBL; AL110224; CAB53682.1; -; mRNA.
DR   CCDS; CCDS14169.1; -. [Q9BYF1-1]
DR   PIR; T14762; T14762.
DR   RefSeq; NP_068576.1; NM_021804.2. [Q9BYF1-1]
DR   UniGene; Hs.178098; -.
DR   PDB; 1R42; X-ray; 2.20 A; A=1-615.
DR   PDB; 1R4L; X-ray; 3.00 A; A=1-615.
DR   PDB; 1XJP; Model; -; B=19-615.
DR   PDB; 2AJF; X-ray; 2.90 A; A/B=19-615.
DR   PDB; 3D0G; X-ray; 2.80 A; A/B=56-615.
DR   PDB; 3D0H; X-ray; 3.10 A; A/B=56-615.
DR   PDB; 3D0I; X-ray; 2.90 A; A/B=56-615.
DR   PDB; 3KBH; X-ray; 3.31 A; A/B/C/D=19-615.
DR   PDB; 3SCI; X-ray; 2.90 A; A/B=19-615.
DR   PDB; 3SCJ; X-ray; 3.00 A; A/B=19-615.
DR   PDB; 3SCK; X-ray; 3.00 A; A/B=83-615.
DR   PDB; 3SCL; X-ray; 3.00 A; A/B=83-615.
DR   PDBsum; 1R42; -.
DR   PDBsum; 1R4L; -.
DR   PDBsum; 1XJP; -.
DR   PDBsum; 2AJF; -.
DR   PDBsum; 3D0G; -.
DR   PDBsum; 3D0H; -.
DR   PDBsum; 3D0I; -.
DR   PDBsum; 3KBH; -.
DR   PDBsum; 3SCI; -.
DR   PDBsum; 3SCJ; -.
DR   PDBsum; 3SCK; -.
DR   PDBsum; 3SCL; -.
DR   ProteinModelPortal; Q9BYF1; -.
DR   SMR; Q9BYF1; -.
DR   BioGrid; 121864; 6.
DR   DIP; DIP-44689N; -.
DR   IntAct; Q9BYF1; 1.
DR   MINT; MINT-4538816; -.
DR   STRING; 9606.ENSP00000252519; -.
DR   BindingDB; Q9BYF1; -.
DR   ChEMBL; CHEMBL3736; -.
DR   DrugBank; DB00722; Lisinopril.
DR   DrugBank; DB00691; Moexipril.
DR   DrugBank; DB05203; SPP1148.
DR   DrugBank; DB05358; TAK-491.
DR   GuidetoPHARMACOLOGY; 1614; -.
DR   MEROPS; M02.006; -.
DR   iPTMnet; Q9BYF1; -.
DR   PhosphoSitePlus; Q9BYF1; -.
DR   BioMuta; ACE2; -.
DR   DMDM; 71658783; -.
DR   EPD; Q9BYF1; -.
DR   PaxDb; Q9BYF1; -.
DR   PeptideAtlas; Q9BYF1; -.
DR   PRIDE; Q9BYF1; -.
DR   Ensembl; ENST00000252519; ENSP00000252519; ENSG00000130234. [Q9BYF1-1]
DR   Ensembl; ENST00000427411; ENSP00000389326; ENSG00000130234. [Q9BYF1-1]
DR   GeneID; 59272; -.
DR   KEGG; hsa:59272; -.
DR   UCSC; uc004cxa.2; human. [Q9BYF1-1]
DR   CTD; 59272; -.
DR   DisGeNET; 59272; -.
DR   GeneCards; ACE2; -.
DR   HGNC; HGNC:13557; ACE2.
DR   HPA; CAB026174; -.
DR   HPA; HPA000288; -.
DR   MIM; 300335; gene.
DR   neXtProt; NX_Q9BYF1; -.
DR   OpenTargets; ENSG00000130234; -.
DR   PharmGKB; PA425; -.
DR   eggNOG; KOG3690; Eukaryota.
DR   eggNOG; ENOG410XPJ3; LUCA.
DR   GeneTree; ENSGT00520000055576; -.
DR   HOGENOM; HOG000292210; -.
DR   HOVERGEN; HBG000265; -.
DR   InParanoid; Q9BYF1; -.
DR   KO; K09708; -.
DR   OMA; CNPNNPQ; -.
DR   OrthoDB; EOG091G033S; -.
DR   PhylomeDB; Q9BYF1; -.
DR   TreeFam; TF312861; -.
DR   BRENDA; 3.4.15.1; 2681.
DR   BRENDA; 3.4.17.23; 2681.
DR   Reactome; R-HSA-2022377; Metabolism of Angiotensinogen to Angiotensins.
DR   SABIO-RK; Q9BYF1; -.
DR   ChiTaRS; ACE2; human.
DR   EvolutionaryTrace; Q9BYF1; -.
DR   GeneWiki; Angiotensin-converting_enzyme_2; -.
DR   GenomeRNAi; 59272; -.
DR   PMAP-CutDB; Q9BYF1; -.
DR   PRO; PR:Q9BYF1; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000130234; -.
DR   CleanEx; HS_ACE2; -.
DR   Genevisible; Q9BYF1; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0045121; C:membrane raft; TAS:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0004180; F:carboxypeptidase activity; IDA:UniProtKB.
DR   GO; GO:0004175; F:endopeptidase activity; IDA:UniProtKB.
DR   GO; GO:0001948; F:glycoprotein binding; IPI:BHF-UCL.
DR   GO; GO:0004181; F:metallocarboxypeptidase activity; EXP:Reactome.
DR   GO; GO:0001618; F:virus receptor activity; IDA:BHF-UCL.
DR   GO; GO:0008270; F:zinc ion binding; TAS:BHF-UCL.
DR   GO; GO:0002005; P:angiotensin catabolic process in blood; IC:BHF-UCL.
DR   GO; GO:0002003; P:angiotensin maturation; TAS:Reactome.
DR   GO; GO:0003051; P:angiotensin-mediated drinking behavior; IMP:BHF-UCL.
DR   GO; GO:0060452; P:positive regulation of cardiac muscle contraction; IEA:Ensembl.
DR   GO; GO:1903598; P:positive regulation of gap junction assembly; IMP:BHF-UCL.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IC:BHF-UCL.
DR   GO; GO:0032800; P:receptor biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0046813; P:receptor-mediated virion attachment to host cell; IDA:BHF-UCL.
DR   GO; GO:0097746; P:regulation of blood vessel diameter; IC:BHF-UCL.
DR   GO; GO:1903779; P:regulation of cardiac conduction; IMP:BHF-UCL.
DR   GO; GO:0042127; P:regulation of cell proliferation; TAS:BHF-UCL.
DR   GO; GO:0001817; P:regulation of cytokine production; IC:BHF-UCL.
DR   GO; GO:0050727; P:regulation of inflammatory response; IC:BHF-UCL.
DR   GO; GO:0003081; P:regulation of systemic arterial blood pressure by renin-angiotensin; IMP:BHF-UCL.
DR   GO; GO:0019229; P:regulation of vasoconstriction; IC:BHF-UCL.
DR   GO; GO:0015827; P:tryptophan transport; IEA:Ensembl.
DR   GO; GO:0046718; P:viral entry into host cell; TAS:UniProtKB.
DR   CDD; cd06461; M2_ACE; 1.
DR   InterPro; IPR033591; ACE2.
DR   InterPro; IPR031588; Collectrin_dom.
DR   InterPro; IPR001548; Peptidase_M2.
DR   PANTHER; PTHR10514; PTHR10514; 1.
DR   PANTHER; PTHR10514:SF31; PTHR10514:SF31; 1.
DR   Pfam; PF16959; Collectrin; 1.
DR   Pfam; PF01401; Peptidase_M2; 1.
DR   PRINTS; PR00791; PEPDIPTASEA.
DR   PROSITE; PS00142; ZINC_PROTEASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Carboxypeptidase; Cell membrane;
KW   Chloride; Complete proteome; Cytoplasm; Direct protein sequencing;
KW   Disulfide bond; Glycoprotein; Host cell receptor for virus entry;
KW   Host-virus interaction; Hydrolase; Membrane; Metal-binding;
KW   Metalloprotease; Polymorphism; Protease; Receptor; Reference proteome;
KW   Secreted; Signal; Transmembrane; Transmembrane helix; Zinc.
FT   SIGNAL        1     17       {ECO:0000255}.
FT   CHAIN        18    805       Angiotensin-converting enzyme 2.
FT                                /FTId=PRO_0000028570.
FT   CHAIN        18    708       Processed angiotensin-converting enzyme
FT                                2.
FT                                /FTId=PRO_0000292268.
FT   TOPO_DOM     18    740       Extracellular. {ECO:0000255}.
FT   TRANSMEM    741    761       Helical. {ECO:0000255}.
FT   TOPO_DOM    762    805       Cytoplasmic. {ECO:0000255}.
FT   REGION       30     41       Interaction with SARS-CoV spike
FT                                glycoprotein.
FT   REGION       82     84       Interaction with SARS-CoV spike
FT                                glycoprotein.
FT   REGION      353    357       Interaction with SARS-CoV spike
FT                                glycoprotein.
FT   REGION      652    659       Essential for cleavage by ADAM17.
FT   REGION      697    716       Essential for cleavage by TMPRSS11D and
FT                                TMPRSS2.
FT   ACT_SITE    375    375
FT   ACT_SITE    505    505
FT   METAL       374    374       Zinc; catalytic.
FT   METAL       378    378       Zinc; catalytic.
FT   METAL       402    402       Zinc; catalytic.
FT   BINDING     169    169       Chloride.
FT   BINDING     273    273       Substrate.
FT   BINDING     345    345       Substrate.
FT   BINDING     346    346       Substrate; via carbonyl oxygen.
FT   BINDING     371    371       Substrate.
FT   BINDING     477    477       Chloride.
FT   BINDING     481    481       Chloride.
FT   BINDING     515    515       Substrate.
FT   CARBOHYD     53     53       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000305|PubMed:14754895}.
FT   CARBOHYD     90     90       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:14754895,
FT                                ECO:0000269|PubMed:15084671}.
FT   CARBOHYD    103    103       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:14754895}.
FT   CARBOHYD    322    322       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000305|PubMed:14754895}.
FT   CARBOHYD    432    432       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:14754895}.
FT   CARBOHYD    546    546       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:14754895,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    690    690       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID    133    141       {ECO:0000269|PubMed:14754895}.
FT   DISULFID    344    361       {ECO:0000269|PubMed:14754895}.
FT   DISULFID    530    542       {ECO:0000269|PubMed:14754895}.
FT   VAR_SEQ     555    555       F -> L (in isoform 2).
FT                                {ECO:0000303|PubMed:12975309}.
FT                                /FTId=VSP_014901.
FT   VAR_SEQ     556    805       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:12975309}.
FT                                /FTId=VSP_014902.
FT   VARIANT      26     26       K -> R (in dbSNP:rs4646116).
FT                                {ECO:0000269|Ref.9}.
FT                                /FTId=VAR_023082.
FT   VARIANT     638    638       N -> S (in dbSNP:rs183135788).
FT                                {ECO:0000269|PubMed:15937940}.
FT                                /FTId=VAR_023083.
FT   MUTAGEN      24     26       QAK->KAE: Slightly inhibits interaction
FT                                with SARS-CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN      31     31       K->D: Abolishes interaction with SARS-CoV
FT                                spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN      37     37       E->A: No effect on interaction with SARS-
FT                                CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN      38     38       D->A: No effect on interaction with SARS-
FT                                CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN      41     41       Y->A: Strongly inhibits interaction with
FT                                SARS-CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN      68     68       K->D: Slightly inhibits interaction with
FT                                SARS-CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN      82     84       MYP->NFS: Inhibits interaction with SARS-
FT                                CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     110    110       E->P: No effect on interaction with SARS-
FT                                CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     135    136       PD->SM: No effect on interaction with
FT                                SARS-CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     160    160       E->R: No effect on interaction with SARS-
FT                                CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     192    192       R->D: No effect on interaction with SARS-
FT                                CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     219    219       R->D: No effect on interaction with SARS-
FT                                CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     239    239       H->Q: No effect on interaction with SARS-
FT                                CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     309    309       K->D: No effect on interaction with SARS-
FT                                CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     312    312       E->A: No effect on interaction with SARS-
FT                                CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     324    324       T->A: No effect on interaction with SARS-
FT                                CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     338    340       NVQ->DDR: No effect on interaction with
FT                                SARS-CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     350    350       D->A: No effect on interaction with SARS-
FT                                CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     353    353       K->H,A,D: Abolishes interaction with
FT                                SARS-CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     355    355       D->A: Strongly inhibits interaction with
FT                                SARS-CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     357    357       R->A: Strongly inhibits interaction with
FT                                SARS-CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     359    359       L->K,A: No effect on interaction with
FT                                SARS-CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     383    383       M->A: Slightly inhibits interaction with
FT                                SARS-CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     389    389       P->A: Slightly inhibits interaction with
FT                                SARS-CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     393    393       R->A: Slightly inhibits interaction with
FT                                SARS-CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     425    427       SPD->PSN: Slightly inhibits interaction
FT                                with SARS-CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     465    467       KGE->QDK: No effect on interaction with
FT                                SARS-CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     559    559       R->S: Slightly inhibits interaction with
FT                                SARS-CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     603    603       F->T: No effect on interaction with SARS-
FT                                CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   CONFLICT     18     18       Q -> H (in Ref. 12; CAB53682).
FT                                {ECO:0000305}.
FT   CONFLICT    508    508       N -> D (in Ref. 8; AAQ89076).
FT                                {ECO:0000305}.
FT   CONFLICT    631    631       K -> R (in Ref. 5; BAB40370).
FT                                {ECO:0000305}.
FT   HELIX        23     52       {ECO:0000244|PDB:1R42}.
FT   HELIX        56     77       {ECO:0000244|PDB:1R42}.
FT   TURN         78     82       {ECO:0000244|PDB:1R42}.
FT   HELIX        85     87       {ECO:0000244|PDB:3D0G}.
FT   HELIX        91    100       {ECO:0000244|PDB:1R42}.
FT   HELIX       104    107       {ECO:0000244|PDB:1R42}.
FT   HELIX       110    129       {ECO:0000244|PDB:1R42}.
FT   STRAND      131    134       {ECO:0000244|PDB:1R42}.
FT   STRAND      137    143       {ECO:0000244|PDB:1R42}.
FT   TURN        144    146       {ECO:0000244|PDB:1R42}.
FT   HELIX       148    154       {ECO:0000244|PDB:1R42}.
FT   HELIX       158    171       {ECO:0000244|PDB:1R42}.
FT   HELIX       173    193       {ECO:0000244|PDB:1R42}.
FT   STRAND      196    198       {ECO:0000244|PDB:1R4L}.
FT   HELIX       199    204       {ECO:0000244|PDB:1R42}.
FT   TURN        205    207       {ECO:0000244|PDB:1R42}.
FT   TURN        213    215       {ECO:0000244|PDB:1R42}.
FT   HELIX       220    251       {ECO:0000244|PDB:1R42}.
FT   TURN        253    255       {ECO:0000244|PDB:1R42}.
FT   STRAND      258    260       {ECO:0000244|PDB:3SCJ}.
FT   HELIX       264    266       {ECO:0000244|PDB:1R42}.
FT   STRAND      267    271       {ECO:0000244|PDB:1R42}.
FT   HELIX       276    278       {ECO:0000244|PDB:1R42}.
FT   HELIX       279    282       {ECO:0000244|PDB:1R42}.
FT   TURN        284    287       {ECO:0000244|PDB:1R42}.
FT   TURN        294    297       {ECO:0000244|PDB:1R42}.
FT   HELIX       298    300       {ECO:0000244|PDB:1R42}.
FT   HELIX       304    316       {ECO:0000244|PDB:1R42}.
FT   TURN        317    319       {ECO:0000244|PDB:1R42}.
FT   HELIX       327    330       {ECO:0000244|PDB:1R42}.
FT   STRAND      338    340       {ECO:0000244|PDB:3D0G}.
FT   STRAND      347    352       {ECO:0000244|PDB:1R42}.
FT   STRAND      355    359       {ECO:0000244|PDB:1R42}.
FT   HELIX       366    384       {ECO:0000244|PDB:1R42}.
FT   TURN        385    387       {ECO:0000244|PDB:1R42}.
FT   HELIX       390    392       {ECO:0000244|PDB:1R42}.
FT   HELIX       400    413       {ECO:0000244|PDB:1R42}.
FT   HELIX       415    420       {ECO:0000244|PDB:1R42}.
FT   TURN        422    426       {ECO:0000244|PDB:1R4L}.
FT   HELIX       432    446       {ECO:0000244|PDB:1R42}.
FT   HELIX       449    465       {ECO:0000244|PDB:1R42}.
FT   STRAND      466    468       {ECO:0000244|PDB:1R4L}.
FT   HELIX       470    472       {ECO:0000244|PDB:1R42}.
FT   HELIX       473    483       {ECO:0000244|PDB:1R42}.
FT   STRAND      486    488       {ECO:0000244|PDB:3D0G}.
FT   HELIX       499    502       {ECO:0000244|PDB:1R42}.
FT   HELIX       504    507       {ECO:0000244|PDB:1R42}.
FT   HELIX       514    531       {ECO:0000244|PDB:1R42}.
FT   TURN        532    534       {ECO:0000244|PDB:1R42}.
FT   HELIX       539    541       {ECO:0000244|PDB:1R42}.
FT   HELIX       548    558       {ECO:0000244|PDB:1R42}.
FT   TURN        559    562       {ECO:0000244|PDB:1R42}.
FT   HELIX       566    574       {ECO:0000244|PDB:1R42}.
FT   STRAND      575    578       {ECO:0000244|PDB:1R42}.
FT   HELIX       582    598       {ECO:0000244|PDB:1R42}.
FT   STRAND      600    602       {ECO:0000244|PDB:1R42}.
FT   STRAND      607    609       {ECO:0000244|PDB:1R42}.
SQ   SEQUENCE   805 AA;  92463 MW;  8EE6EB0A931550E8 CRC64;
     MSSSSWLLLS LVAVTAAQST IEEQAKTFLD KFNHEAEDLF YQSSLASWNY NTNITEENVQ
     NMNNAGDKWS AFLKEQSTLA QMYPLQEIQN LTVKLQLQAL QQNGSSVLSE DKSKRLNTIL
     NTMSTIYSTG KVCNPDNPQE CLLLEPGLNE IMANSLDYNE RLWAWESWRS EVGKQLRPLY
     EEYVVLKNEM ARANHYEDYG DYWRGDYEVN GVDGYDYSRG QLIEDVEHTF EEIKPLYEHL
     HAYVRAKLMN AYPSYISPIG CLPAHLLGDM WGRFWTNLYS LTVPFGQKPN IDVTDAMVDQ
     AWDAQRIFKE AEKFFVSVGL PNMTQGFWEN SMLTDPGNVQ KAVCHPTAWD LGKGDFRILM
     CTKVTMDDFL TAHHEMGHIQ YDMAYAAQPF LLRNGANEGF HEAVGEIMSL SAATPKHLKS
     IGLLSPDFQE DNETEINFLL KQALTIVGTL PFTYMLEKWR WMVFKGEIPK DQWMKKWWEM
     KREIVGVVEP VPHDETYCDP ASLFHVSNDY SFIRYYTRTL YQFQFQEALC QAAKHEGPLH
     KCDISNSTEA GQKLFNMLRL GKSEPWTLAL ENVVGAKNMN VRPLLNYFEP LFTWLKDQNK
     NSFVGWSTDW SPYADQSIKV RISLKSALGD KAYEWNDNEM YLFRSSVAYA MRQYFLKVKN
     QMILFGEEDV RVANLKPRIS FNFFVTAPKN VSDIIPRTEV EKAIRMSRSR INDAFRLNDN
     SLEFLGIQPT LGPPNQPPVS IWLIVFGVVM GVIVVGIVIL IFTGIRDRKK KNKARSGENP
     YASIDISKGE NNPGFQNTDD VQTSF
//
